# Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC

> **NCT04313504** · PHASE2 · COMPLETED · sponsor: **Trisha Wise-Draper** · enrollment: 10 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Niraparib
- **DRUG:** Dostarlimab

## Key facts

- **NCT ID:** NCT04313504
- **Lead sponsor:** Trisha Wise-Draper
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-04
- **Primary completion:** 2025-06-01
- **Final completion:** 2026-03-04
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04313504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04313504, "Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC". Retrieved via AI Analytics 2026-05-20 from https://api.ai-analytics.org/clinical/NCT04313504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*